Episode 10: Taking the Pressure Off: ACE Inhibitors
In our tenth episode, we discuss our second choice of hyperåtensive medication agent, the ACE inhibitor. We review dosing and renal protection (briefly) before agreeing our choice is based mostly on once a day adminstration and costs. We look at substituting with ARBs but not combining with ARBs (with possible exception of co-morbid CHF). Throughout the podcast, James disagrees with Mike on a variety of issues, more on principle than fact.
Show Notes
1) A meta-analysis of ACE inhibitors/ARBs versus other antihypertensive drugs on renal outcomes – in diabetics, no difference in end-stage renal disease or doubling of creatinine – albuminuria was reduced but remember this is a surrogate endpoint
2) Telmisartan produced the same outcome as ramipril in diabetics – the combination did not add benefit but increased adverse events
3) Combining ACEs and ARBs in heart failure did produce a benefit
Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!
